Part 5/14:

A recurring theme is the influence of large pharmaceutical firms. Dr. Hatfield lambasts the collaboration between drug companies and regulatory agencies, such as the FDA’s apparent resistance to approving or even acknowledging the efficacy of early treatment drugs. He points out conflicts of interest, including Pfizer and Moderna’s financial ties and the revolving door of personnel between health agencies and biotech companies, suggesting a lack of genuine scientific independence.

Origins of COVID-19: Natural or Laboratory?